Insulet Corporation Stock News

The U.S. stock market staged a remarkable rally in 2023, but 173 stocks in the S&P 500 were still down for the year.

Investors are optimistic about Insulet (PODD), led by the strong adoption of Omnipod 5 and its strong solvency position.

Baird is bullish on Boston Scientific, Insulet, and DexCom, stocks set to benefit as those companies ramp up sales.

Here is how to utilize the Filtered Zacks Rank 5 Stock Screen to help find potentially winning stocks to buy to close out December and throughout 2024.

We have narrowed our search to five Nasdaq Composite listed laggards of 2023 with strong potential for 2024. These are: PEP, KHC, WMG, PODD, BGNE.

Insulet (PODD) possesses solid growth attributes, which could help it handily outperform the market.

Integra expands the international reach of the CUSA platform and registers DuraGen, DuraSeal, Mayfield and Duo LED lighting in the EMEA and Latin America.

Five momentum stocks for December are: NVDA, VRT, CPRT, CEG, PODD.

Invest in stocks such as Insulet (PODD), W.R. Berkley (WRB), Invitation Home (INVH) and VICI Properties (VICI) for superb earnings growth.

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management

Insulet (PODD) possesses solid growth attributes, which could help it handily outperform the market.

Insulet (PODD) continues to gain from the strong adoption of Ommipod 5 and market expansion.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Rank.

Insulet (PODD) could produce exceptional returns because of its solid growth attributes.

The 2023 version of the U.S.